Literature DB >> 34012642

Mitofusin-2 is a novel anti-angiogenic factor in pancreatic cancer.

Zhichuan Lin1, Xiaoyi Lin1, Jinhong Chen1, Guoqiang Huang1, Tangen Chen1, Liling Zheng2.   

Abstract

BACKGROUND: Aberrant expression of mitofusin-2 (MFN2) has been found to be associated with vascular endothelial growth factor A (VEGFA)-mediated angiogenesis in human umbilical vein endothelial cells (HUVECs). This study aimed to investigate the expression of MFN2 in pancreatic cancer (PC) and the role of MFN2 in vascular endothelial cell growth and angiogenesis.
METHODS: Protein and mRNA expression of MFN2 and VEGFA were measured. The CCK-8 assay, tube formation assay, flow cytometry, and transmission electron microscopy were used to examine the effects of MFN2 overexpression on HUVEC growth, angiogenesis, and apoptosis. Western blot and immunocytochemical staining were conducted to measure alterations in cell cycle and apoptosis regulators and vascular endothelial growth factor receptor 2 (VEGFR2), angiopoietin-1 gene (ANGPT1), and tissue inhibitor of metalloproteinase 1 (TIMP1) expression in HUVECs.
RESULTS: The results showed that MFN2 levels were significantly decreased in tumor tissues. Contrasting results were observed for VEGFA mRNA levels. MFN2 overexpression inhibited cell growth while promoting the formation of apoptotic bodies in HUVECs. Additionally, MFN2 overexpression enhanced the protein expression of p21 and p27 while attenuating the expression of proliferating cell nuclear antigen, VEGFA, VEGFR2, ANGPT1, and TIPM1 in HUVECs.
CONCLUSIONS: In conclusion, MFN2 expression negatively correlates with VEGFA expression in PC and inhibits endothelial cell growth and angiogenesis. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Pancreatic cancer (PC); angiogenesis; mitofusin-2 (MFN2); vascular endothelial growth factor A (VEGFA)

Year:  2021        PMID: 34012642      PMCID: PMC8107624          DOI: 10.21037/jgo-21-176

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  34 in total

1.  Mitofusin 2 ablation increases endoplasmic reticulum-mitochondria coupling.

Authors:  Riccardo Filadi; Elisa Greotti; Gabriele Turacchio; Alberto Luini; Tullio Pozzan; Paola Pizzo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

2.  The anti-tumor effects of Mfn2 in breast cancer are dependent on promoter DNA methylation, the P21Ras motif and PKA phosphorylation site.

Authors:  Yufeng Li; Wenyue Dong; Xijin Shan; Hui Hong; Yan Liu; Yankun Liu; Xiaohui Liu; Xiaojun Zhang; Jinghua Zhang
Journal:  Oncol Lett       Date:  2018-03-21       Impact factor: 2.967

3.  Cell-cycle arrest at G2/M and proliferation inhibition by adenovirus-expressed mitofusin-2 gene in human colorectal cancer cell lines.

Authors:  X Cheng; D Zhou; J Wei; J Lin
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

4.  Anti-tumour efficacy of mitofusin-2 in urinary bladder carcinoma.

Authors:  Baiye Jin; Guanghou Fu; Hao Pan; Xiaofei Cheng; Lin Zhou; Jia Lv; Geming Chen; Shusen Zheng
Journal:  Med Oncol       Date:  2010-08-28       Impact factor: 3.064

5.  Dysregulation of HSG triggers vascular proliferative disorders.

Authors:  Kuang-Hueih Chen; Xiaomei Guo; Dalong Ma; Yanhong Guo; Qian Li; Dongmei Yang; Pengfei Li; Xiaoyan Qiu; Shaojun Wen; Rui-Ping Xiao; Jian Tang
Journal:  Nat Cell Biol       Date:  2004-08-22       Impact factor: 28.824

Review 6.  Anticancer strategies involving the vasculature.

Authors:  Victoria L Heath; Roy Bicknell
Journal:  Nat Rev Clin Oncol       Date:  2009-05-07       Impact factor: 66.675

Review 7.  An overview of small-molecule inhibitors of VEGFR signaling.

Authors:  S Percy Ivy; Jeannette Y Wick; Bennett M Kaufman
Journal:  Nat Rev Clin Oncol       Date:  2009-09-08       Impact factor: 66.675

8.  Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.

Authors:  Hiroki Yamaue; Takuya Tsunoda; Masaji Tani; Motoki Miyazawa; Kenji Yamao; Nobumasa Mizuno; Takuji Okusaka; Hideki Ueno; Narikazu Boku; Akira Fukutomi; Hiroshi Ishii; Shinichi Ohkawa; Masayuki Furukawa; Hiroyuki Maguchi; Masafumi Ikeda; Yosuke Togashi; Kazuto Nishio; Yasuo Ohashi
Journal:  Cancer Sci       Date:  2015-05-14       Impact factor: 6.716

9.  Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors.

Authors:  Gray R Anderson; Suzanne E Wardell; Merve Cakir; Catherine Yip; Yeong-Ran Ahn; Moiez Ali; Alexander P Yllanes; Christina A Chao; Donald P McDonnell; Kris C Wood
Journal:  Nat Commun       Date:  2018-04-26       Impact factor: 14.919

10.  Mitofusin2 Induces Cell Autophagy of Pancreatic Cancer through Inhibiting the PI3K/Akt/mTOR Signaling Pathway.

Authors:  Ran Xue; Qinghua Meng; Di Lu; Xinjuan Liu; Yanbin Wang; Jianyu Hao
Journal:  Oxid Med Cell Longev       Date:  2018-06-26       Impact factor: 6.543

View more
  3 in total

Review 1.  Mitochondrial dynamics regulators: implications for therapeutic intervention in cancer.

Authors:  Sanjay Kumar; Rahail Ashraf; Aparna C K
Journal:  Cell Biol Toxicol       Date:  2021-10-18       Impact factor: 6.691

Review 2.  Divergent Roles of Mitochondria Dynamics in Pancreatic Ductal Adenocarcinoma.

Authors:  Cristian Andres Carmona-Carmona; Elisa Dalla Pozza; Giulia Ambrosini; Andrea Errico; Ilaria Dando
Journal:  Cancers (Basel)       Date:  2022-04-26       Impact factor: 6.575

Review 3.  Mitofusins: from mitochondria to fertility.

Authors:  Shanjiang Zhao; Nuo Heng; Huan Wang; Haoyu Wang; Haobo Zhang; Jianfei Gong; Zhihui Hu; Huabin Zhu
Journal:  Cell Mol Life Sci       Date:  2022-06-20       Impact factor: 9.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.